Glimed-MF 2/1000 SR Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in better glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual and prolonged drug release, minimizing gastrointestinal side effects commonly associated with Metformin and improving patient compliance. Glimed-MF 2/1000 SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Dose adjustments may be necessary based on individual patient response and tolerability. Contraindications include severe renal impairment, diabetic ketoacidosis, and hypersensitivity to either component. This combination therapy offers a synergistic approach to managing hyperglycemia, contributing to effective long-term diabetes management when used under medical supervision.